top of page

Unlocking new Aptamer therapeutics with Generative AI

Learn more about PentaBind

Targeting of Any Protein

We're developing our therapeutic drug assets to target previously 'Undruggable' human proteins; the largest class of human proteins and a driver of multiple cancers and diseases.

 

Our proprietary AI-based platform applies a powerful Generative AI approach to enable the design of aptamers (short, single-stranded DNA or RNA sequences) with ‘drug-like qualities’, a balancing of multiple design features including binding, specificity, stability etc. Traditional wet-lab aptamer design (SELEX) only designs for binding and so, for the past 20 years, aptamers have been mostly limited to academia.
 

The time for aptamer therapeutics is now. Key aptamer patents recently expired, the 2nd aptamer drug received FDA approval in August 2023 and the successes of mRNA vaccines and gene therapies helped to de-risk aptamer drugs.

WHO WE ARE

A Platform TechBio Company

PentaBind is a platform TechBio company consisting of bioinformaticians, data scientists, biophysicists, engineers and synthetic biology experts, who's CEO is a serial entrepreneur (1x biotech exit). They are backed by the prolific venture capital firm, Entrepreneur First and supported by Panacea Stars and P4SY.

vis_fig.png

PentaBind

Generative Algorithms and Aptamers will unlock the next generation of therapeutics

GET IN TOUCH

Contact us for partnership or investment enquiries. For job opportunities please apply via our Careers webpage.

  • LinkedIn
London City
Subscribe

Subscribe To Our Mailing List

Thanks for submitting!

SUPPORTED BY

bottom of page